Skip to main content
. Author manuscript; available in PMC: 2020 Dec 7.
Published in final edited form as: N Engl J Med. 2020 Jun 4;382(23):2207–2219. doi: 10.1056/NEJMoa1915315

Figure 2. Event-free Survival and Overall Survival, According to Treatment Group.

Figure 2.

Shown are Kaplan–Meier estimates of event-free survival (i.e., freedom from primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer) and of overall survival. Vertical bars represent the Rothman 95% confidence intervals; point estimates of 36-month event-free survival and overall survival with 95% confidence intervals are shown.